Device/Diagnostics Quarterly Deal Statistics, Q4 2016
A look at the financing, M&A and alliance activity October–December 2016
Medtech companies raised $2.4 billion in the fourth quarter, the second-strongest of the year; Q4 device M&A deals totaled $9 billion in value, led by Allergan's $2.9 billion buy of Acelity's LifeCell division. Diagnostics financings finished out the year at $721 million, an increase over the previous quarter and 2016's second-highest quarter, but diagnostics M&A activity was the lowest of the year at $87 million, with only two completed acquisitions.
You may also be interested in...
Allergan Gets Regen Med Assets, Acelity Gets Cash Boost Post-IPO Dump
Allergan has agreed to acquire Acelity's LifeCell division for $2.9bn. The deal will give Allergan entry to the regenerative medicine sector and expand its aesthetics portfolio, while the substantial cash consideration should console Acelity after ditching plans for an IPO.
BSN medical Investment Pays Off For EQT In €2.7bn Deal
BSN medical is changing owners for the third time in a decade, with a multi-billion-euro deal that will see the wound-care and orthopedics specialist enter the folds of SCA, a Swedish group that sells consumer health-care products, among other things.
Philips, Masimo Bury Hatchet Over Patient-Monitoring Battle
Philips and Masimo have put to rest their long legal wrangling over patient-monitoring technology patents and shaken hands on a multi-year, global sales, and marketing partnership.